
During the second half of 2022, Genmab and partner Abbvie will submit an application for marketing authorization from the FDA concerning their candidate epcoritamab. The target indication is relapsed/refractory large B-cell lymphoma (LBCL).
The application will be based on the results of the partners’ Epcore study, which generated positive top-line data in April.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app